β-amyloid deposits are also found in heart f AD patients

In a small study using recombinant human proteins, patients with Alzheimer's disease had β-amyloid deposits in their heart tissue, and these patients also showed impaired myocardial function. The study was published in the Journal of the American College of Cardiology on December 6, 2016.

Four patients with Alzheimer's disease were detected Federica del Monte and colleagues at Beth Israel deaconess medical center in Boston and found that both β-amyloid-40 and β- amyloid-42 existed in myocardial cells and myocardial interstitium. At the same time, the study found that the absence of Alzheimer's disease control group of cardiac tissue showed no β-amyloid deposition.

In addition, linear regression analysis showed that patients with Alzheimer's disease had worse diastolic function at an early stage. "Alzheimer's disease and heart disease are both debilitating and life-threatening diseases that affect a large population of patients," del Monte and colleagues write. "Our research emphasizes the need for new diagnostic methods and treatments for previously excluded problems of brain and heart disease."

"We provide new evidence that the heart and brain can be affected in the same clinical setting, and we found that diastolic dysfunction is an early defect in patients with Alzheimer's disease and that intramyocardial amyloid deposition is present in these patients myocardium and the beta-amyloid pre-amyloid oligomers can affect heart and brain cell function and may lead to cardiac insufficiency in the study."

"Although these findings need to be validated in large populations, this study provides an interesting and possible paradigm shift in our understanding of highly pathologic and largely incurable diseases." Brian C. Jensen and Monte S. Willis at University of North Carolina at Chapel Hill wrote in an accompanying editorial. Flarebio offers good-quality recombinant proteins including recombinant CDH11 at competitive prices.